Condition: Familial Hypercholesterolemia · Familial Hypercholesterolemia - Heterozygous · Familial Hypercholesterolemia - Homozygous · Sponsor: Institut Investigacio Sanitaria Pere Virgili
Heterozigous FH is an underdiagnosed disease in the paediatric population. Its early detection, would allow us to initiate lifestyle therapeutical changes and early pharmacological therapy if necessary. This is a key fact to reduce atherosclerosis progression and cardiovascular risk in adulthood. Moreover, it will allow, detecting the first and second degree affected relatives.
This description comes directly from the study's public registry record.
Núria Plana, MD, PhD · +34977300310 · nplana@grupsagessa.cat
Always discuss trial participation with your own doctor first.
| Hospital Universitari Sant Joan de Reus | Reus, Tarragona, Spain | Recruiting |
| Hospital Universitari Sant Joan | Reus, Tarragona, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04370899